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QA3
DOES COST-EFFECTIVENESS ANALYSIS DISCRIMINATE AGAINST PATIENTS
WITH SHORTER LIFE EXPECTANCY?
Paulden M, Culyer AJ
University of Toronto, Toronto, ON, Canada
OBJECTIVES: The UK’s National Institute for Health and Clinical Excellence (NICE)
has been accused of discriminating against patientswith shorter life expectancy by
embracing the use of quality-adjusted life years (QALYs) within cost-effectiveness
analysis (CEA). The basis of this claim is that patients with shorter life expectancy
have fewer QALYs to gain from treatment and so NICE’s guidance inherently dis-
criminates against such patients. Such criticisms may also be directed at similar
decision making agencies. Our objective was to formally identify the circum-
stances under which CEA-based decision-making discriminates on the basis of life
expectancy. METHODS: We developed a simple model of a CEA-based decision
making process in which a technology is considered cost-effective for a particular
patient cohort only if the ICER for that cohort lies below a fixed cost-effectiveness
threshold. For such decisionmaking to discriminate on the basis of life expectancy,
the ICERs for two hypothetical cohorts of patients – identical in all ways except life
expectancy – must lie on either side of the threshold. RESULTS:We find that CEA
does not inherently discriminate on the basis of life expectancy but that scope for
discrimination arises in the case of specific technologies having identifiable char-
acteristics. Such discrimination may in fact favour those patients with shorter life
expectancy. In all cases the use of discounting is shown to reduce the likelihood of
discrimination on the basis of life expectancy – this is particularly relevant in light
of the recent discussion around NICE’s discounting practices. CONCLUSIONS: It is
recommended that agencies such as NICE consider the possibility of discrimina-
tion arising from their use of CEA. Accusations of inherent discrimination, how-
ever, appear to be misplaced. It is argued that these claims are founded upon a
fundamentalmisunderstanding of the role of QALYs in CEA, particularlywithin the
decision rules adopted by policy makers.
QA4
IS THE AIM OF THE HEALTH CARE SYSTEM TO MAXIMISE QALYS? AN
INVESTIGATION OF ‘WHAT ELSE MATTERS’ IN THE NHS
Praet C1, Shah K2, Devlin N3, Sussex J2, Parkin D4, Appleby J5
1Merck, London, UK, 2Office of Health Economics, University of Sheffield, London, UK, 3Office of
Health Economics, London, UK, 4NHS South East Coast, London, UK, 5King’s Fund, London, UK
OBJECTIVES: It is often assumed that the objective of health care is solely to max-
imise health using available resources. This is the principle underpinning NICE’s
use of cost-effectiveness analysis based on incremental cost per QALY gained. Yet
research on local NHS decision-making shows that cost per QALY is far from the
only consideration. Similarly, many national NHS policy initiatives are driven pri-
marily not by QALY gain, but by ‘process-of-care’ and other considerations. The DH
is required to undertake and publish Impact Assessments (IAs) identifying the
costs and benefits expected fromall newpolicy implementation.We analyse all IAs
carried out in 2008-2009 to identify the benefits considered by the DH as relevant to
its decision making. METHODS: The stated benefits of each policy were extracted
from the relevant IA. A combination of methods was used to categorise these.
RESULTS: 51 IAs were analysed, 8 of whichmentioned QALY gains as a benefit. 162
benefits other than QALY gains were identified. Apart from improving health out-
comes, common types of benefit included reducing costs, improving quality of
care, and enhancing patient experience and empowerment. CONCLUSIONS:Many
of the policies reviewed were implemented on the basis of benefits unrelated to
health outcome. The methods being used to apply a monetary valuation to QALY
gains (in IA cost-benefit calculations) are not consistent across IAs, or with NICE’s
stated threshold range.We consider the implications for NHS decisionmaking and
NICE guidance, and the meaning of allocative efficiency in the NHS.
POSTER SESSION I:
HEALTH CARE USE & POLICY STUDIES
Health Care Use & Policy Studies – Consumer Role in Health Care
PHP1
USE OF STRUCTURAL EQUATION MODELING TO EXPLAIN CONSUMER
BEHAVIOR TOWARDS GENERIC DRUG DISCOUNT PROGRAMS
Patel HK, Sansgiry S
University of Houston, Houston, TX, USA
OBJECTIVES: The study attempts to assess the robustness of constructs with the
Theory of Planned Behavior (TPB) in explaining intention to use generic drug dis-
count programs (GDDPs). METHODS: A self-administered questionnaire was dis-
tributed to consumers filling a prescription at pharmacies in Houston (Texas, USA)
that offered GDDPs (CVS,Walgreens,Wal-Mart, Kroger, Target, Randalls, andH-E-B
stores). Constructs of TPB, namely, consumer’s attitude towards GDDPs, perceived
behavioral control (PBC), subjective norms (SN), and intention to use were mea-
sured using a pre-validated 5 point likert scale. The questionnaire also measured
consumer awareness regarding GDDPs, attitude towards generic drugs in general
alongwith demographic data. Structural equationmodeling (SEM) using AMOS v18
was used to test the proposed model. RESULTS: Response rate of 59.46% was ob-
tained (n  389). Scales developed to measure all the domains were reliable ( 
0.72-0.89). Majority (68.4%) of respondents were aware of GDDPs. Mean attitude
towards GDDPs (4.080.83) and intention to use (4.331.01) scores were high. The
SEM best fitmodel was the one where association of awareness with intention was
mediated by attitude towards GDDPs as there was no direct relationship (CMIN/df
3.29; p0.001; CFI0.904; RMSEA0.077). Further, attitude towards generics was
retained in the model and exerted a higher indirect effect on intention via attitude
towards GDDPs. The effect of PBC on intention was very low and SN was not
retained in the model. CONCLUSIONS: As pharmacy stores develop prescription
drug plans usingGDDPs to increase utilization and increase store loyalty, strategies
to improve consumer attitude towards generics and GDDPs will be useful. Contin-
uous information regarding these programs may increase awareness of such pro-
grams leading to a positive attitude and increased use.
PHP2
TRENDS IN AND PREDICTORS OF DISCOUNT GENERIC MEDICATION PROGRAM
UTILIZATION
Gatwood J, Tungol A, Truong C, Erickson S
University of Michigan, Ann Arbor, MI, USA
OBJECTIVES: To examine the trends in use and characteristics of patients using
discount generic prescription programs. METHODS: A cross-sectional survey of
patients in the University ofMichigan TaubmanGeneral Medicine Clinic was taken
over the course of two, four week intervals, first in the summer of 2008 and again in
2010. The survey was given in-person, in paper format, and was completed while
patients were waiting to see their physician. Self-reported information was gath-
ered on the patients’most recent prescriptionmedication use in two parts: a listing
of current medications (location of filling, price paid, brand/generic, discount pro-
gram use) and inquiries on program use, if applicable, as well as patient
demographics. RESULTS: The overall convenience sample over the two cohorts
included 414 individuals, 203 in 2008 and 211 in 2010. The sample was mostly
Caucasian (78.7%),most patients had prescription drug insurance coverage (92.1%),
and a large majority of medications filled were for chronic use (84.3%). Patient
demographics between the two populations were similar for all characteristics
with two exceptions: a higher mean number of medications was reported in 2010,
4.2 versus 3.4 (t  3.07, p0.01), and 29.9% of those surveyed in 2010 had used a
discount medication program versus 5.4% in 2008 (X2  42.10, p0.001). Factors
associated with program use included patient age 50 – 64 years (OR, 3.79; 95%
confidence interval [CI], 1.45 – 9.95; p0.004), an annual household income of less
than $24000 (OR, 2.64; CI, 1.12 – 6.22; p0.02), and the filling of medications for
chronic use (OR, 1.86; CI, 1.20 – 2.88; p0.005). CONCLUSIONS: Limited differences
in patientsmost likely to use discount prescriptionmedication programs existed in
the studied population. More extended analysis of such program utilization is
needed to better understand patient use of such services.
PHP3
FEDERAL ENFORCEMENT ACTIONS AGAINST FRAUD AND ABUSE BY
PHARMACEUTICAL MANUFACTURERS: 1996-2010
Qureshi Z1, Sartor O2, Bennett C1
1University of South Carolina, Columbia, SC, USA, 2Tulane University, New Orleans, LA, USA
OBJECTIVES: To expand on the scope of the limited prior research by reporting on
concluded investigations involving pharmaceuticalmanufacturers independent of
whether or not they involved qui tam relators between 1996-2010. METHODS: All
cases involved pharmaceutical manufacturers and FCA violations, which impose
liability of up to triple damages and civil penalties of $5,500 to $11,000 per claim for
submitting false claims to the government. Data were from Department of Justice
during 1996-2010. RESULTS: Since 1996, resolution of 31 FCA cases involving phar-
maceutical manufacturers accounted for $12 billion in recoveries. Total recoveries
were $8 million during 1996-2000 (one case), $3.9 billion during 2001-2005 (15
cases), and $8.1 billion during 2006- 2010 (15 cases). Billing fraud was implicated in
18 cases ($3.7 billion), off-label marketing in 12 cases ($4.4 billion), kick-backs in 5
cases ($1.7 billion), and producing defective pharmaceuticals in one case ($750
million).Qui tam relators initiated 77% of the cases (median reward $31million). Six
settlements included criminal fines. CONCLUSIONS: With expansion of govern-
ment healthcare, fraud investigations of pharmaceutical manufacturers will un-
doubtedly continue. These investigations have the potential to reduce costs and
improve the quality of pharmaceutical use.
PHP4
WHEN STAKEHOLDERS DON’T AGREE: DISCREPANCIES IN MAB “APPROVALS”
OVER THE PAST TEN YEARS
Miller KL, Stevens CA
PAREXEL Consulting, Waltham, MA, USA
OBJECTIVES: In the drug development process the priorities of the stakeholders
(manufacturers, payers, regulators, patients, physicians) often do not align, and at
times are in conflict, e.g. in the US consumers aren’t concerned about cost, but
private payers are.With cost as a significant driver tomultiple decisionmakers, we
explore monocolonal antibodies (mAb) as a drug class and the handling of their
approvals and authorizations by the US and UK key bodies.METHODS: The follow-
ing sources were summarized for mAbs approved in the past 10 years: the regula-
tory approval decision in the United States and the United Kingdom; the payer
coverage decision, if applicable and available; relevant patient advocacy groups’
statements; and statements on behalf of medical organizations. Discrepancies be-
tween initial regulatory decisions and the statements of the other stakeholders
were highlighted. RESULTS: These sources show the use of clinical data to advo-
cate differing stakeholders’ views. In the case of natalizumab, patient advocacy
groups and regulators disagreed on whether the risks outweighed the drug bene-
fits. In judging the value of bevacizumab for breast cancer patients, regulators and
payers are still at odds. Furthermore, the debate between the payers and the man-
ufacturer on the use of off-label bevacizumab seems to hinge on the clinical results
from the US National Eye Institute. CONCLUSIONS: Although physicians continue
to play a critical role in determining drug use once a product is approved, other
stakeholders (e.g. patients and independent researchers) are increasing their sway
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in themarket. Given the discrepancies between the decisions of the regulators and
the payers, drug manufacturers are obliged to demonstrate a product’s value to
patients and payers, as well as to show that it is safe and efficacious to regulators.
The incorporation of the payers’ viewpoint in the development process will ease
the gap between stakeholders.
PHP5
INCENTIVE-BASED INTERVENTIONS – REWARDING PATIENTS FOR GOOD
BEHAVIOUR
Haynes S, Costello S, Brooks-Rooney C, Hamer N
Costello Medical Consulting Ltd, Cambridge, UK
OBJECTIVES: Incentive-based schemes, in which patients are rewarded formaking
behaviour changes or reaching treatment goals, are becoming more common in
healthcare worldwide. Issues surrounding the cost effectiveness of behaviour
change, as well as the ethical implications of rewarding members of society who
exhibit inappropriate behaviours, are some of the issues which must be taken into
account when considering these schemes in real-life. The aim of this study was to
provide an account of incentive-based schemes currently under investigation, in
an effort to determine where the perceived benefits of these schemes may lie for
future implementation. METHODS: A Clinicaltrials.gov search was performed to
identify trials that specifically tested the use of incentives in encouraging behav-
iour modification in target populations. RESULTS: A total of 76 clinical trials, pre-
dominantly based in North America, were identified as appropriate for analysis.
The most commonly targeted groups included drug dependant individuals, over-
weight individuals (with exercise orweight-loss programmes) and smokers, imply-
ing that these schemes are most commonly used to induce lifestyle changes that
promote health. Most trials looked at the clinical-effectiveness of incentives at
achieving behaviour change, with minimal emphasis on the cost-effectiveness of
adding the incentive. The majority of the trials (43/76, 57%) used monetary or
voucher reimbursement systems as the incentive for patient behaviour modifica-
tion, with 10 additional schemes providing the opportunity to win a prize. Only 1
scheme directly linked reimbursement to treatment costs by providing a cycle of
treatment for free if the patient sustained compliance for a specified period.
CONCLUSIONS: The scope for the use of incentive-based schemes is broad, with
potential applications in numerous different diseases in which good compliance is
required; not just those which require lifestyle change. However, further economic
analysis of the cost-effectiveness of such schemes is essential before they are
implemented more widely.
Health Care Use & Policy Studies – Diagnosis Related Group
PHP6
EXPLORE THE USE OF DRUGS IN MEDICAL INSURANCE BILLING IN CHINA
Tan Z
Ministry of Labor and Social Security, Beijing, China
OBJECTIVES: With the advancement of the China health care reform and the in-
creasing health care expenditure, it is imperative to explore other billing methods
in addition to the existing item-based billing. Since 1980s, US and many other
countries have adopted DRGs to manage heath care insurance to control health
care expenditure and achieved positive outcomes. The objectives of this study are
to understand experiences from other countries in the implementation of DRGs
and make recommendations on how to adopt DRGs in China. METHODS: This
study started in 2003. It is composed of three phases: phase one is to study how
DRGs are implemented in the US, Australia, and Germany; phase two, the core part
of this study, is to analyze the grouping method. Based on learnings from US,
Australia, and Germany, we randomly collected 700000 patient records taking
place between 2002 and 2005 from 12 tier-one Beijing hospitals, developed a theo-
retical DRGs grouping model, and completed over 600 DRGs automated grouping
programs tailored for China; phase three contains analyses on the basic require-
ment of relevant policy and technology support to implement DRGs. RESULTS:
DRGs has been demonstrated to be an effective approach to manage health care
insurance in many countries. Considering China’s special situations (population,
health insurance system and policy environment), we developed and piloted DRGs
in 12 tier-one hospitals in Beijing in 2010. We will further evaluate the impact of
this program in the future. CONCLUSIONS: The successful implementation of
DRGs depends on an appropriate policy environment and mature technology sup-
port. Currently China is not ready to launch DRGs nationally yet due to the lack of
policy environment and technology support.
Health Care Use & Policy Studies – Drug/Device/Diagnostic Use & Policy
PHP7
DEVELOPING PUBLIC HEALTH GUIDANCE - WHAT ARE THE DATA GAPS?
REVIEW OF THE GAPS IN THE EVIDENCE IDENTIFIED BY NICE IN THE UNITED
KINGDOM
Kusel J, Costello S, Hamer N, Roper S, Hamerslag L
Costello Medical Consulting Ltd, Cambridge, UK
OBJECTIVES: Public health policy is understood to be a major determinant of over-
all population health. However, developing public health guidance can be difficult
due to the lack of sufficient evidence on the effectiveness and cost-effectiveness of
possible interventions. The objective of this studywas to identify themajor gaps in
the evidence base that has been used to develop public health guidance.
METHODS: The gaps identified by the UK National Institute for Health and Clinical
Excellence (NICE) in the evidence that was used for the development of their 31
public health guidance documents published as of December 2010 were assessed
and compared. RESULTS: The most prevalent data gap, identified by 25 of the 31
guidance documents, was a lack of evidence on the effectiveness of public health
interventions in specific subgroups of the population, particularly ethnic minori-
ties, age subgroups and those from disadvantaged backgrounds. The secondmajor
gap in the evidence, discussed by 21 documents, was a lack of data specific to the
country of interest (in this case, the UK). Nineteen documents reported the lack of
cost-effectiveness evidence as a barrier to developing public health guidance and 4
of these specifically noted the difficulty of generating QALYs in the public health
arena. Further major data gaps included a lack of well-designed studies (14 docu-
ments), a lack of long-term outcomes (13), insufficient evaluation of which ele-
ments of an interventionmake it effective (9) and a lack of evidence on the relative
effectiveness of interventions (8). CONCLUSIONS: Research into public health in-
terventions and issues is of paramount importance. Researchers should focus ef-
forts upon identifying particular subgroups in which interventions are particularly
effective or ineffective and on generating country-specific data. Cost-effectiveness
data is particularly lacking; one solution would be to devise newmethods of QALY
measurement in public health situations.
PHP8
PHYSICIAN SHORTAGE IMPACT ON PATIENT RX USE FOR SELECT CHRONIC
CONDITIONS
Dall T1, Seiders M2, Price P2, Chakrabarti R1, Tal S1, Kowal S1, Larson J1
1IHS, Washington, DC, USA, 2AstraZeneca Pharmaceuticals LP, Wilmington, DE, USA
OBJECTIVES: This study investigates the extent to which geographic variation in
adequacy of primary care and specialist supply explains variation in patient use of
prescribed medications to treat chronic conditions. METHODS: Generalized Least
Squares regression with period random effects was used on a pooled data set of
monthly (May 2006 to Oct 2010) IMS Health data for 360 Metropolitan Statistical
Areas (MSAs). The dependent variablewas totalmonthly prescriptions perMSA for:
(1) Statins, (2) PPIs, (3) Anti-psych, and (4) asthma/COPD. Separate regressionswere
estimated by therapeutic category and by payer type. Explanatory variables include
monthly: (1) size of the population with the chronic condition;(2) economic envi-
ronment; (3) dummy event variables; and (4) level of Rx advertising. Estimates of
the shortfall of primary care providers and specialists in each State in 2010 are
included as explanatory variables. For state-level shortfall, provider demand esti-
mates were based on national healthcare use and delivery patterns applied to each
State’s population controlling for demographics, rates of uninsured, and obesity
rates. RESULTS: There exists a direct correlation between estimated adequacy of
primary care and specialist (cardiologist, gastroenterologist, psychiatrist, pul-
monologist, and allergist) supply and volume of prescriptions. The patterns are
relatively consistent across therapeutic areas. For the Statinmarket, each 1% short-
fall of cardiologists is associated with 0.36%, 0.43%, and 0.79% decrease in Statin Rx
volume for the commercially insured,Medicare, andMedicaid populations, respec-
tively. Each 1% shortfall of primary care providers is associated with decreases in
volume across in the commercially insured (0.15%) and Medicaid (0.83%)
populations. CONCLUSIONS: This research suggests that controlling for economic
and population risk factors, greater inadequacy of physician supply is associated
with lower use of prescriptions for treating chronic conditions. Physician shortages
disproportionally affect access to medications for the Medicaid population, fol-
lowed by the Medicare and commercially insured populations.
PHP9
IMPACT OF FREE PRESCRIPTIONS IN WALES ON PRESCRIBING - A THIN
DATABASE STUDY
Thompson M, Sedani T, Blak BT, Hards M
Cegedim Strategic Data Medical Research Ltd, London, UK
OBJECTIVES: The Welsh Assembly Government introduced free prescriptions for
all on 1st April 2007. In the other UK countries, prescriptions were around £6 each,
although children, elderly and other exemptions applied. This study evaluated
whether the Welsh policy change impacted levels of prescribing.METHODS: Total
numbers of prescription itemswere calculated for eight 12-month periods between
1st July 2001 and 30th June 2009 from The Health Improvement Network (THIN),
which contains anonymised longitudinal UK primary care data. The number of
prescriptions was divided by number of actively registered patients for each time
period, country and age category (0-21, 22-59 and 60 years old). Percentage
changes between periods were calculated and all results described. RESULTS: In
Wales therewere 19.5 prescriptions/patient in the 2001/2002 period, which steadily
increased to 26.9 in the 2008/2009 period. In England, prescriptions/patient in-
creased from 15.1 to 21.3, Scotland 15.4 to 20.2, Northern Ireland (NI) 16.7 to 21.9.
The percentage change between 2006/2007 and 2007/2008 was 4.2% in Wales, 4.9%
England, 3.1% Scotland, 4.3% NI. The change within the 0-21 year olds was 4.0%,
1.7%, 2.6% and 0.8% respectively. For 22-59 year olds it was 6.6%, 3.0%, 2.5% and
3.7% respectively. For 60 year olds it was 2.8%, 5.1%, 2.9% and 4.3% respectively.
CONCLUSIONS: The descriptive results suggest that overall the policy change did
not seem to impact levels of prescribing in Wales as the percentage change was
similar across countries. However, the percentage change for the 0-21 and 22-59
age groups was higher in Wales, whereas the percentage change for the 60 age
group, who were already exempt from prescription charges, was lower. This could
suggest that prescribing increased for patients who were previously most affected
by prescription charges. Future studies could evaluatewhether prescribing of certain
drug classes, especially those including over-the-counter products, was affected.
PHP10
THE TEMPORAL ASSOCIATION BETWEEN PRESCRIBED OPIOIDS AND THE
NATIONAL DEATH RATE DUE TO OPIOID POISONING
Gokhale MN, Martin B
University of Arkansas for Medical Sciences, Little Rock, AR, USA
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